CSPC Pharmaceutical Gets NMPA Approval for ATM Inhibitor SYH2051 Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
VIVA Biotech Holdings Divests Stake in Shanghai Unit to Temasek-Backed Entities
China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has agreed to sell a...
China Medical System’s Diazepam Nasal Spray Receives NMPA Approval for Cluster Seizures
China-based China Medical System Holdings Ltd (CMS; HKG: 0867) has announced receiving New Drug Application...
Dizal Pharmaceutical Presents Updates on DZD8586 and Golidocitinib at ICML
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented updates on the clinical development of its...
AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class...
Abbisko Therapeutics Initiates Phase II Study for Pimicotinib in Chronic Graft-Versus-Host Disease
Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing...
NHSA Launches 2023 NRDL Update Process with New Work Plan and Public Feedback Period
The National Healthcare Security Administration (NHSA) has commenced the process for the annual update of...
Genor Biopharma’s Geptanolimab NDA for PTCL Rejected by China’s NMPA
China’s Genor Biopharma Co., Ltd (HKG: 6998) has announced that the National Medical Products Administration...
CSPC Pharmaceutical’s CPO301 Earns Fast-Track Status for EGFR Mutant NSCLC Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate...
Salubris Pharmaceuticals’ Enarodustat Gains NMPA Approval for Renal Anemia Treatment
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving market approval from the...
Baheal Pharmaceutical Partners with RabPharma for Commercialization of RAB001 in China
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with...
CDE Releases 71st Batch of Generic Reference Preparations with Updates and New Injecables
The Center for Drug Evaluation (CDE) has released the 71st batch of chemical generic reference...
Hainan Boao Lecheng Partners with Recordati on Rare Disease Drug Development
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has announced a strategic partnership with...
NMPA Approves Shanghai Magic Medicine’s Innovative Multimodal Tumor Treatment System
The National Medical Products Administration (NMPA) has granted marketing approval to Shanghai Magic Medicine’s multimodal...
Keymed Biosciences’ CM313 Monoclonal Antibody Shows Promise in Phase I Study for Multiple Myeloma
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that the latest results from a Phase...
Eccogene Secures $25 Million in Series B Financing to Advance Metabolic Disease Therapies
Sino-US firm Eccogene Inc. has announced the closure of a Series B financing round, raising...
HutchMed Presents Updated Data on Hematological Malignancy Therapies at EHA and ICML
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that new and updated clinical data...
Reistone Biopharma’s Ivarmacitinib Accepted for Review by China’s CDE for Atopic Dermatitis
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...
CDE Indicates Priority Review for Overland ADCT’s Zynlonta and BeiGene’s Brukinsa
The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)...
Kexing Pharmaceutical Secures Commercial Rights for Convalife’s Neratinib Generic Outside China
China-based Kexing Pharmaceutical (SHA: 688136) has announced a licensing agreement with compatriot firm Convalife, securing...